May 1 |
Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M
|
May 1 |
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
|
Apr 30 |
UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval
|
Apr 30 |
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
|
Apr 30 |
Neurocrine Biosciences Q1 2024 Earnings Preview
|
Apr 30 |
Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
|
Apr 25 |
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
|
Apr 24 |
Neurocrine launches CAH community website ahead of FDA filing
|
Apr 24 |
Neurocrine Biosciences upgraded at Wells Fargo on pipeline
|
Apr 24 |
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
|